Wells Fargo analyst Vik Chopra initiated coverage of Masimo with an Equal Weight rating and $173 price target. The analyst likes the predictability of the company’s healthcare business and sees potential upside from new consumer health products in 2024 and beyond. However, the firm expects management to remain distracted with the ongoing proxy contest and sees the uncertainty as “far from over.” The proxy overhang is Wells’ primary source of concern for the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MASI: